Evaluate the Safety of Linaclotide in IBS-C Patients in China

AstraZeneca3,028 enrolled

Overview

This is a Multi-center, single arm, observational study to evaluate the safety of linaclotide in IBS-C patients in China. Enrolls approximately 3,000 Chinese patients from 30 participating sites around China and followed up for half year.

This is a multi-center, one arm, prospective observational study which enrolls approximately 3,000 Chinese patients in China.The study will be performed under real world clinical practice setting. Patients will be eligible for the study after taking at least one dose of linaclotide. Every patient will be followed maximum of 6 months after enrollment. Study measures will be collected at baseline and during the follow-up period. Incidence of adverse events will be employed to assess the safety and tolerability of linaclotide in Chinese patients. The treatment satisfaction will be employed to assess the impact of treatment. The Irritable Bowel Syndrome-Quality of Life Measure (IBS-QoL) will be employed to assess the patient's quality of life.

Study Type

OBSERVATIONAL

Enrollment

3,028

Conditions

Irritable Bowel Syndrome-IBS

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≧ 18 years old * Provision of subject informed consent prior to any study procedures * Has taken at least one dose of linaclotide * NOT participating in any interventional study currently or during the last 3 months Exclusion Criteria: * If linaclotide is contraindicated according to the product prescribing information * Being unable to comply with study-specified procedure * Has ever participated in current study before -

Locations (29)

Research Site

Baotou, China

Research Site

Outcomes

Primary Outcomes

Demonstrate the safety of linaclotide therapy

The primary objective of current study is to demonstrate the safety of linaclotide therapy by assessment of the incidence of any adverse events (AEs) , serious adverse events (SAEs) , AEs by severity, ADRs and AEs leading to linaclotide-associated interruption, discontinuation, and death during 6-month follow up in Chinese patients.

Time frame: 2023/09/30

Secondary Outcomes

Assess the treatment satisfaction

To observe patients' treatment satisfaction status after treatment via a 5-point treatment satisfaction scale (1=not at all, 2=a little, 3=somewhat, 4=very, 5=extremely)

Time frame: 2023/09/30

Assess the impact of linaclotide treatment in patient's quality of life.

To describe patient's quality of life after treatment via the Irritable Bowel Syndrome-Quality of Life Measure (IBS-QoL).

Time frame: 2023/09/30

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.